|1.||Böhm, Michael: 10 articles (01/2015 - 11/2002)|
|2.||Sowers, James R: 10 articles (09/2012 - 01/2009)|
|3.||van Veldhuisen, Dirk J: 9 articles (10/2012 - 01/2007)|
|4.||Giles, Thomas D: 8 articles (04/2015 - 07/2009)|
|5.||Tavazzi, Luigi: 8 articles (01/2015 - 11/2002)|
|6.||Coats, Andrew J S: 8 articles (08/2014 - 11/2002)|
|7.||Flather, Marcus D: 8 articles (08/2014 - 11/2002)|
|8.||Fici, Francesco: 8 articles (10/2013 - 08/2005)|
|9.||Habibi, Javad: 8 articles (09/2012 - 01/2009)|
|10.||SENIORS Investigators: 7 articles (08/2014 - 02/2005)|
|1.||Hypertension (High Blood Pressure)
04/01/2008 - "Nebivolol (Bystolic), a novel, highly cardioselective, third-generation beta-blocker that recently received approval by the US FDA for the treatment of hypertension in the USA, is effective in treating blood pressure and has a favorable side-effect profile. "
09/01/2010 - "Nebivolol is effective in mild-to-moderate hypertension and associated with favorable metabolic effects. "
01/01/2007 - "Unlike first generation beta-blockerrs, vasodilator beta-blockerrs such as nebivolol have favorable hemodynamic effects, which may translate into improved cardiovascular outcomes in patients with hypertension."
11/01/2001 - "Therefore, nebivolol may be recommended as an alternative first-line treatment option for the management of patients with mild to moderate essential hypertension."
09/01/2010 - "Nebivolol is effective in treating patients with diabetes suffering from high blood pressure and metabolic syndrome. "
03/01/2006 - "SENIORS study using nebivolol provides best evidence of effective treatment for heart failure in the elderly."
08/01/2006 - "For example, the vasodilating beta-blocker nebivolol was shown to improve forearm blood flow and arterial stiffness and, in a large clinical study, to significantly reduce morbidity and mortality, independent of left ventricular ejection fraction, among patients with chronic heart failure. "
07/01/2006 - "One long-term trial showed a significant reduction in death and hospital admissions for cardiovascular causes when nebivolol was compared with placebo in patients with heart failure (31.1% vs 65.3%; HR 0.86; 95% CI 0.74 to 0.99). "
01/01/2006 - "Only the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (which used the vasodilating third-generation beta-adrenoceptor antagonist nebivolol) has prospectively investigated the treatment of CHF in elderly patients, including those with preserved systolic function, and demonstrated a significant reduction in the risk of death or cardiovascular hospitalisation. "
01/01/2002 - "Treatment with nebivolol was associated with lowering of systolic and diastolic blood pressure (by 22% and 26%, respectively), significant reduction of left ventricular mass index, improvement of parameters of systolic and diastolic left ventricular function and lowering of NYHA class of heart failure. "
11/01/2009 - "Our study contributes to understand the efficacy of nebivolol on serum protein/peptide profiles during atherosclerosis development."
06/01/2010 - "Our results show that nebivolol treatment may be beneficial to improve oxidative stress parameters in patients with SCF, which are considered to be an early stage of atherosclerosis."
12/01/2009 - "This is the first report showing the effect of nebivolol on atherogenesis in gene-targeted mice."
12/01/2009 - "Nebivolol attenuated atherogenesis, measured both by "en face" method (9.23+/-1.8% vs. 14.6+/-2.1%) and "cross-section" method (63125+/-8455 microm(2) vs. 91416+/-8357 m(2)). "
11/01/2009 - "Proteomic profiling during atherosclerosis progression: Effect of nebivolol treatment."
01/01/2014 - "The lack of an inhibitory effect of inflammation on the clearance of nebivolol is suggestive of mechanisms other than an efficient hepatic metabolism for its low bioavailability. "
09/01/2009 - "Our aim was to investigate the efficacy of nebivolol in patients with slow coronary flow by monitoring its effects on endothelial function and different markers of inflammation. "
01/01/2014 - "The consistency of response to nebivolol despite inflammation may be due to the predominance of contribution of β2 and β3-AR. "
01/01/2014 - "The action and disposition of nebivolol were, however, unaffected by inflammation despite the reduced β1-AR levels. "
01/01/2014 - "We studied whether response to nebivolol is also reduced by inflammation. "
10/01/2015 - "The results of this study suggest that nebivolol has protective effects on liver but not on distant organs in a hepatic ischemia/reperfusion injury model. "
10/01/2015 - "These experimental findings indicate that nebivolol may be useful in the treatment of hepatic ischemia/reperfusion injury."
10/01/2015 - "Nebivolol Ameliorates Hepatic Ischemia/Reperfusion Injury on Liver But Not on Distant Organs."
01/01/2008 - "Nebivolol reduces experimentally induced warm renal ischemia reperfusion injury in rats."
11/01/2004 - "The protective effect of nebivolol on ischemia/reperfusion injury in rabbit spinal cord."
|4.||Nitric Oxide (Nitrogen Monoxide)
|5.||Nitric Oxide Synthase (NO Synthase)
|6.||NADPH Oxidase (NAD(P)H oxidase)
|1.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)